NTRK1 and cancer: In total, 10 out of 12 pathways from the “Signaling by Receptor Tyrosine Kinases” super-pathway (https://reactome.org/PathwayBrowser/#/R-HSA-9006934&PATH=R-HSA-162582) are affected through cancer-type specific mutation signatures.Signaling by EGFR is the most recurrently perturbed pathway, being affected in 65% (17 out of 26) cancer types.